Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

US-based Halia Therapeutics’ new therapy will be put to a six-month-long trial that will involve 60 patients with type 2 ...

Prostate cancer imaging developed by university researchers has shown “extremely encouraging” results in its first clinical ...

The antiviral pill Paxlovid might help some patients who are suffering from long COVID.A five-day course of Paxlovid ...

As the curtain closed on 2024, FDA issued a new draft guidance to assist clinical trial sponsors, investigators, and institutional review ...

BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.

The company announced that the first subjects have been dosed in a Phase-1 clinical trial of SUVN-I6107 in the USA.

Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.

Suven Life Sciences surged 9.51% to Rs 138.70 after the firm dosed first subjects in a Phase-1 clinical trial of SUVN-I6107 being conducted in USA under FDA acceptance of investigational new drug (IND ...